Ozempic: A Potential Game-Changer for Mental Health in Bipolar Disorder
A groundbreaking new study published in Acta Psychiatrica Scandinavica has unveiled that semaglutide — the active ingredient in the renowned weight-loss and diabetes drugs Ozempic and Wegovy — could provide substantial mental health benefits for individuals diagnosed with bipolar disorder.
The research team at Griffith University, spearheaded by Professor Mark Taylor, meticulously analyzed 15 years of Swedish national health registry data, encompassing nearly 15,000 patients with bipolar disorder. The findings were remarkable: patients administered with semaglutide exhibited a 21% lower risk of psychiatric hospitalization compared to periods when they were not under the medication.
It is hypothesized by scientists that GLP-1 signaling might aid in safeguarding the brain by mitigating inflammation, cellular stress, and other biological processes associated with bipolar disorder. This could potentially lead to enhanced mood stability and a decreased risk of relapse. Interestingly, other drugs in the same GLP-1 receptor agonist class — including liraglutide and dulaglutide — did not demonstrate the same mental health correlation, making semaglutide’s effect particularly noteworthy.
Professor Taylor advocates for a randomized controlled trial as the subsequent step to validate whether semaglutide could eventually play an official role in bipolar disorder treatment. According to the World Health Organization, bipolar disorder impacts an estimated 37 million people worldwide.
Source: ScienceDaily — Ozempic and Wegovy may have an unexpected mental health benefit